532
Participants
Start Date
August 1, 2021
Primary Completion Date
March 1, 2025
Study Completion Date
March 1, 2027
PD-1 blocking antibody
"1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. IMRT phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of IMRT or CCRT and continue every 3 weeks for 3 cycles till the end of IMRT.~3. Adjuvant PD-1 blocking antibody: every 3 weeks × 11 cycles; 240 mg, day 1"
Gemcitabine
Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles
Cisplatin (80mg/m2)
Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles
Cisplatin (100mg/m2)
Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
Intensity-modulated radiotherapy
Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
Panyu central hospital, Guangzhou
Beijing Cancer Hospital, Beijing
Chongqing Cancer Hospital, Chongqing
First People's Hospital of Foshan, Foshan
Cancer Hospital of Guangxi Medical University, Nanning
Cancer Hospital of Guizhou Medical University, Guiyang
Hubei Province Cancer Hosiptal, Wuhan
Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan
Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan
Xiangya Hospital Central South University, Changsha
Jiangxi Province Cancer Hospital, Nanchang
Zhejiang Province Cancer Hospital, Hangzhou
Shanghai Junshi Bioscience Co., Ltd.
OTHER
Sun Yat-sen University
OTHER